Investigating Brown Adipose Tissue in Patients with Pheochromocytoma or Paraganglioma
The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)
This study is trying to see how brown fat works in people with pheochromocytoma or paraganglioma by using special scans to understand its role in their metabolism.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | King's College Hospital NHS Trust Academic / other |
| Locations | 1 site (London, United Kingdom of Great Britain and Northern Ireland) |
| Trial ID | NCT06440122 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the incidence and outcomes of metabolically active brown adipose tissue (aBAT) in patients diagnosed with pheochromocytoma or paraganglioma. It utilizes FDG-PET scans to evaluate the presence and activation of brown adipose tissue, which plays a crucial role in thermogenesis and metabolism. The study focuses on understanding how various factors, such as adrenergic stimulation, influence the metabolic activity of brown fat in these patients. By analyzing the data collected, researchers hope to gain insights into the relationship between aBAT and these specific tumors.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with confirmed pheochromocytoma or paraganglioma who have undergone an FDG-PET scan as part of their staging process.
Not a fit: Patients with other neoplasms besides pheochromocytoma or paraganglioma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of brown adipose tissue's role in metabolic processes, potentially leading to improved management strategies for patients with pheochromocytoma or paraganglioma.
How similar studies have performed: While the investigation of brown adipose tissue is a growing field, this specific focus on its role in pheochromocytoma and paraganglioma is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with confirmed pheochromocytoma or paraganglioma who have undergone a FDG-PET as part of staging process. Exclusion Criteria: * Patients with any other neoplasm other than pheochromocytoma or paraganglioma
Where this trial is running
London, United Kingdom of Great Britain and Northern Ireland
- King's College Hospital NHS Foundation Trust — London, United Kingdom of Great Britain and Northern Ireland, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Georgios Dimitriadis — King's College Hospital NHS Trust
- Study coordinator: Georgios K Dimitriadis
- Email: g.dimitriadis@nhs.net
- Phone: 0777615084
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.